The risk of dyspnea in patients treated with third-generation P2Y12 inhibitors compared with clopidogrel: a meta-analysis of randomized controlled trials

Peer Review reports

Original Submission
6 Jan 2020	Submitted	Original manuscript
6 Feb 2020	Reviewed	Reviewer Report - Gideon Charach
14 Feb 2020	Reviewed	Reviewer Report - Johnny Chahine
1 Mar 2020	Author responded	Author comments - Na Zhang
Resubmission - Version 2
1 Mar 2020	Submitted	Manuscript version 2
Publishing
5 Mar 2020	Editorially accepted
17 Mar 2020	Article published	10.1186/s12872-020-01419-y

Back to article page